Skip to content

Assessment of patient preference of follow-up in cardiac stent trials

Patient Preference Analysis of Yearly Follow-up After PCI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON22823
Enrollment
2550
Registered
2014-06-26
Start date
2013-07-04
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient preference, follow-up, percutaneous coronary intervention, TWENTE trial, DUTCH PEERS trial

Interventions

All subjects will receive a questionnaire with questions regarding their preference with regards of the approach of acquiring follow-up information after PCI. Patient and procedural characteristics

Sponsors

Cardio Research Enschede (CRE), Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients enrolled in the percutaneous coronary intervention (PCI) studies TWENTE trial (a broad study population reflecting real-world PCI patients) and DUTCH PEERS trial (an all-comers population), who were treated at Thoraxcentrum Twente in Enschede between June 2008 and May 2012

Exclusion criteria

Exclusion criteria: Patients who had withdrawn their consent for participation in the TWENTE and DUTCH PEERS trials, respectively. Patients who passed away during follow-up could obviously not be approached for further questioning

Design outcomes

Primary

MeasureTime frame
Assessment of preferred approach for annual follow-up after PCI

Secondary

MeasureTime frame
- Least preferred approach for follow up - Relation between most and least preferred approach of assessment in relation to age, gender, urgency of PCI treatment, history of previous revascularization

Contacts

Public ContactH. Verheij

Medisch Spectrum Twente Haaksbergerstraat 55

h.verheij@ziekenhuis-mst.nl+31 (0)53 4872105

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)